Funding, launches and regulatory moves across the neurotech startup map.
Subscribed. Check your inbox to confirm.
•
Neurofounders Insights
$ Funding -
Series C+
MODALITY
Others
FORM FACTOR
Implant
INTERFACE DEPTH
Minimally invasive
INDICATION
Epilepsy
TARGET USER
Patients
REGULATORY STAGE
CE-Marked
Precisis is developing a minimally invasive epilepsy neuromodulation system, positioning itself as a more targeted alternative to broader neurostimulation approaches. Its CE-marked status gives it a stronger clinical foothold than many epilepsy-device startups.
PRECISIS partnered with Odin Healthcare to introduce EASEE, its minimally invasive brain stimulation implant for drug-resistant focal epilepsy, in the Gulf states, starting with the UAE.